Descriptive only
Acute pancreatitis
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)Separate part 2 of a disconnected network
13
Randomized trials
12
Treatments
5,849
Participants
7
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 13 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteOutcome assessment, time point: selected time points span 16.1 to 111 weeks
- NoteOutcome assessment, analysis set: mixed: randomized 1, safety 12
- NoteOutcome assessment, definition: mixed: deaths 1, investigator reported pancreatitis 1, not stated 10, serious adverse events 1
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 12, while_on_treatment 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 12, treatment_policy 1
- NoteRisk of bias, blinding: mixed: double_blind 12, open_label 1
- NoteRisk of bias, funding: mixed: industry 12, mixed 1
- NoteData handling, input conversions: arms_combined 11
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02717858 | 16.1 | safety | serious adverse events | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2016 | age 18 to 64, BMI 27 or more, no diabetes, no gallbladder disease |
| STEP 1 | 75 | safety | not stated | not stated | not stated | not stated | while_on_treatment | treatment_policy | double_blind | industry | 2018 | adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent |
| STEP 5 | 111 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent |
| NCT05579977 | 28 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes |
| BARIOPTIMISE | 28 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2018 | adults at least 1 year after RYGB or sleeve gastrectomy with 20 percent or less weight loss and suboptimal GLP-1 response |
| VENTURE | 19 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age over 18; BMI 30 or more, or 27 or more with comorbidity; BMI 50 or less; no diabetes |
| NCT05616013 | 48 | safety | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2022 | adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg |
| NCT02075281 | 26 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes |
| NCT04904913 | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Chinese adults 18 to 75; BMI 28 or more, or 24 or more with comorbidity or hyperphagia; no diabetes, HbA1c below 6.5 |
| NCT03856047 | 26 | safety | investigator reported pancreatitis | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes |
| NCT05623839 | 27 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes |
| NCT06250946 | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent |
| NCT01557166 | 34 | safety | deaths | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2012 | age 18 to 64; BMI 30 or more; AHI 15 or more; no diabetes; unable or unwilling to use CPAP |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT02717858 | A1 | LIRA_SC | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| NCT02717858 | A2 | PLACEBO | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| STEP 1 | A1 | SEMA_SC | 75 | arm, events | 3 / 1,306 | R0023399:Table 3 | |||
| STEP 1 | A2 | PLACEBO | 75 | arm, events | 0 / 655 | R0023399:Table 3 | |||
| STEP 5 | A1 | SEMA_SC | 111 | arm, events | 0 / 152 | R0021896:Table 3 | |||
| STEP 5 | A2 | PLACEBO | 111 | arm, events | 0 / 152 | R0021896:Table 3 | |||
| NCT05579977 | A1+A8 | PLACEBO | 28 | arm, events | 0 / 139 | arms_combined | R0004106:Results | ||
| NCT05579977 | A10+A11+A12+A13+A2+A3+A4+A5+A6+A9 | LOTI_PO | 28 | arm, events | 0 / 690 | arms_combined | R0004106:Results | ||
| NCT05579977 | A7 | SEMA_PO | 28 | arm, events | 0 / 73 | R0004106:Results | |||
| BARIOPTIMISE | A1 | PLACEBO | 28 | arm, events | 0 / 35 | R0017334:Results | |||
| BARIOPTIMISE | A2 | LIRA_SC | 28 | arm, events | 0 / 35 | R0017334:Results | |||
| VENTURE | A1 | PLACEBO | 19 | arm, events | 0 / 35 | R0011224:Table 3 | |||
| VENTURE | A2+A3+A4+A5 | VK2735_SC | 19 | arm, events | 0 / 141 | arms_combined | R0011224:Table 3 | ||
| NCT05616013 | A1 | PLACEBO | 48 | arm, events | 1 / 56 | R0015266:Table 3 | |||
| NCT05616013 | A2+A3 | OTHER_ACTIVE_bimagrumab | 48 | arm, events | 1 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A4+A5 | SEMA_SC | 48 | arm, events | 1 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A6+A7+A8+A9 | BIMASEMA_SC | 48 | arm, events | 0 / 225 | arms_combined | R0015266:Table 3 | ||
| NCT02075281 | A1 | PLACEBO | 26 | arm, events | 0 / 60 | R0011218:Results | |||
| NCT02075281 | A2+A3+A4+A5 | EFPE_SC | 26 | arm, events | 0 / 237 | arms_combined | R0011218:Results | ||
| NCT04904913 | A1+A2+A3 | MAZD_SC | 36 | arm, events | 0 / 186 | arms_combined | R0016107:Results | ||
| NCT04904913 | A4 | PLACEBO | 36 | arm, events | 0 / 62 | R0016107:Results | |||
| NCT03856047 | A1+A2+A3+A4+A5 | OTHER_ACTIVE_cagrilintide | 26 | arm, events | 0 / 506 | arms_combined | R0017871:Results | ||
| NCT03856047 | A6 | LIRA_SC | 26 | arm, events | 1 / 99 | R0017871:Results | |||
| NCT03856047 | A7 | PLACEBO | 26 | arm, events | 0 / 101 | R0017871:Results | |||
| NCT05623839 | A1 | PLACEBO | 27 | arm, events | 0 / 8 | R0013210:Supplement Table S2 | |||
| NCT05623839 | A2+A3 | MAZD_SC | 27 | arm, events | 0 / 24 | arms_combined | R0013210:Supplement Table S2 | ||
| NCT06250946 | A1 | PLACEBO | 36 | arm, events | 0 / 46 | R0001289:Table 6 | |||
| NCT06250946 | A2+A3+A4+A5 | HRS7535_PO | 36 | arm, events | 0 / 189 | arms_combined | R0001289:Table 6 | ||
| NCT01557166 | A1 | LIRA_SC | 34 | arm, events | 0 / 180 | R0026203:Results | |||
| NCT01557166 | A2 | PLACEBO | 34 | arm, events | 0 / 179 | R0026203:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.